Non-invasive Testing of Lung Inflammation and Infection in Asthma and Cystic Fibrosis Using Breath Condensate Biomarkers

What this Trial Is About

Researchers are exploring non-invasive ways to detect lung injury, inflammation, and infections in chronic lung diseases such as cystic fibrosis CF and bronchial asthma AB. This study focuses on collecting exhaled breath condensate EBC to identify unique molecular breathprints that indicate pulmonary inflammation and bacterial infections, particularly from pathogens like Pseudomonas aeruginosa. The goal is to link these breathprints with disease severity and respiratory microbiota in CF and AB patients. Participants include children and adults with moderate or IgE-mediated asthma, individuals with cystic fibrosis, and healthy controls without lung disease. Breath condensate samples will be collected and analyzed using high-resolution mass spectrometry to identify biomarkers. The study tracks changes before and after treatments such as antibiotics for CF and inhaled corticosteroids or bronchodilators for asthma, assessing lung disease activity and treatment effects. During the 18 months following screening, participants will undergo lung function tests, blood tests for enzymes like amylase and lipase, microbiological cultures, and imaging scans including CT and X-rays for CF patients. Researchers will monitor inflammatory biomarkers and respiratory health, aiming to validate EBC as a useful diagnostic and monitoring tool. The study involves healthy volunteers and offers a detailed look at pulmonary conditions without invasive procedures.

Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.